PMID- 34697922
OWN - NLM
STAT- MEDLINE
DCOM- 20220203
LR  - 20220203
IS  - 1976-555X (Electronic)
IS  - 1229-845X (Print)
IS  - 1229-845X (Linking)
VI  - 22
IP  - 6
DP  - 2021 Nov
TI  - Potential of polylactic-co-glycolic acid (PLGA) for delivery Jembrana disease DNA 
      vaccine Model (pEGFP-C1-tat).
PG  - e76
LID - 10.4142/jvs.2021.22.e76 [doi]
LID - e76
AB  - BACKGROUND: The development of a vaccine for Jembrana disease is needed to 
      prevent losses in Indonesia's Bali cattle industry. A DNA vaccine model 
      (pEGFP-C1-tat) that requires a functional delivery system will be developed. 
      Polylactic-co-glycolic acid (PLGA) may have potential as a delivery system for 
      the vaccine model. OBJECTIVES: This study aims to evaluate the in vitro potential 
      of PLGA as a delivery system for pEGFP-C1-tat. METHODS: Consensus and codon 
      optimization for the tat gene was completed using a bioinformatic method, and the 
      product was inserted into a pEGFP-C1 vector. Cloning of the pEGFP-C1-tat was 
      successfully performed, and polymerase chain reaction (PCR) and restriction 
      analysis confirmed DNA isolation. PLGA-pEGFP-C1-tat solutions were prepared for 
      encapsulated formulation testing, physicochemical characterization, stability 
      testing with DNase I, and cytotoxicity testing. The PLGA-pEGFP-C1-tat solutions 
      were transfected in HeLa cells, and gene expression was observed by fluorescent 
      microscopy and real-time PCR. RESULTS: The successful acquisition of transformant 
      bacteria was confirmed by PCR. The PLGA:DNA:polyvinyl alcohol ratio formulation 
      with optimal encapsulation was 4%:0.5%:2%, physicochemical characterization of 
      PLGA revealed a polydispersity index value of 0.246, a particle size of 925 nm, 
      and a zeta potential value of -2.31 mV. PLGA succeeded in protecting pEGFP-C1-tat 
      from enzymatic degradation, and the percentage viability from the cytotoxicity 
      test of PLGA-pEGFP-C1-tat was 98.03%. The PLGA-pEGFP-C1-tat demonstrated 
      luminescence of the EGFP-tat fusion protein and mRNA transcription was detected. 
      CONCLUSIONS: PLGA has good potential as a delivery system for pEGFP-C1-tat.
CI  - (c) 2021 The Korean Society of Veterinary Science.
FAU - Unsunnidhal, Lalu
AU  - Unsunnidhal L
AUID- ORCID: 0000-0002-0874-6590
AD  - Department of Reproduction and Obstetrics, Faculty of Veterinary Medicine, 
      University Gadjah Mada, Yogyakarta 55281, Indonesia.
AD  - Biomedical Field, Nursing Study Program, STIKES Yarsi Mataram, West Nusa Tenggara 
      83361, Indonesia.
FAU - Wasito, Raden
AU  - Wasito R
AUID- ORCID: 0000-0002-7454-6618
AD  - Department of Pathology, Faculty of Veterinary Medicine, University Gadjah Mada, 
      Yogyakarta 55281, Indonesia.
FAU - Nugraha Setyawan, Erif Maha
AU  - Nugraha Setyawan EM
AUID- ORCID: 0000-0003-0920-7086
AD  - Department of Reproduction and Obstetrics, Faculty of Veterinary Medicine, 
      University Gadjah Mada, Yogyakarta 55281, Indonesia.
FAU - Warsani, Ziana
AU  - Warsani Z
AUID- ORCID: 0000-0002-6630-5953
AD  - Research Center of Biotechnology, University Gadjah Mada, Yogyakarta 55281, 
      Indonesia.
FAU - Kusumawati, Asmarani
AU  - Kusumawati A
AUID- ORCID: 0000-0001-9828-4969
AD  - Department of Reproduction and Obstetrics, Faculty of Veterinary Medicine, 
      University Gadjah Mada, Yogyakarta 55281, Indonesia.
AD  - Department of Pathology, Faculty of Veterinary Medicine, University Gadjah Mada, 
      Yogyakarta 55281, Indonesia. uma_vet@ugm.ac.id.
LA  - eng
GR  - Direktorat Riset dan Pengabdian Masyarakat/Indonesia
GR  - Lembaga Pengelolaan Dana Pendidikan Republik Indonesia/Indonesia
PT  - Journal Article
DEP - 20210830
PL  - Korea (South)
TA  - J Vet Sci
JT  - Journal of veterinary science
JID - 100964185
RN  - 0 (Vaccines, DNA)
RN  - 0 (Viral Vaccines)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
SB  - IM
MH  - Animals
MH  - Cattle
MH  - Cattle Diseases/*prevention & control
MH  - Diagnostic Tests, Routine
MH  - HeLa Cells
MH  - Humans
MH  - Lentivirus Infections/prevention & control/*veterinary
MH  - *Polylactic Acid-Polyglycolic Acid Copolymer
MH  - *Vaccines, DNA/administration & dosage
MH  - Viral Vaccines/*administration & dosage
PMC - PMC8636661
OTO - NOTNLM
OT  - DNA vaccine
OT  - Jembrana disease
OT  - PLGA
OT  - delivery system
OT  - tat gene
COIS- The authors declare no conflicts of interest.
EDAT- 2021/10/27 06:00
MHDA- 2022/02/04 06:00
PMCR- 2021/08/30
CRDT- 2021/10/26 06:46
PHST- 2021/05/05 00:00 [received]
PHST- 2021/07/26 00:00 [revised]
PHST- 2021/08/03 00:00 [accepted]
PHST- 2021/10/27 06:00 [pubmed]
PHST- 2022/02/04 06:00 [medline]
PHST- 2021/10/26 06:46 [entrez]
PHST- 2021/08/30 00:00 [pmc-release]
AID - 22.e76 [pii]
AID - 10.4142/jvs.2021.22.e76 [doi]
PST - ppublish
SO  - J Vet Sci. 2021 Nov;22(6):e76. doi: 10.4142/jvs.2021.22.e76. Epub 2021 Aug 30.